Calcium homeostasis remains unaffected after 12 weeks' therapy with calcitriol 3 µg/g ointment; no correlation with extent of psoriasis

Reductions in the global severity score and BSA involvement, as well as results of the assessment of improvement, attested to the clinical efficacy of calcitriol 3 microg/g ointment in psoriasis. The study confirms the systemic safety of calcitriol 3 microg/g in psoriatic patients with 5-35% BSA involvement.